Could a yeast and butyrate mix keep UC in check?
NCT ID NCT07591012
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a dietary supplement called ButyMixx in 40 adults with ulcerative colitis who are in remission. ButyMixx contains sodium butyrate and a beneficial yeast to support gut health. Participants take two sachets daily for 8 weeks, and researchers check for symptom changes, quality of life, and gut inflammation. The goal is to see if the supplement is safe and helps maintain remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of UC confirmed by clinical, endoscopic and histopathological evidence. Disease in remission phase confirmed by clinical, endoscopic and histopathological evidence. * Age between 18 and 75 years old * Ability of subject to participate fully in all aspects of this clinical trial. Exclusion Criteria: * Patients that have active UC, determined by clinical, endoscopic and histopathological evidence * Known diagnosis of CD( Crohn disease), indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis or microscopic colitis * Positive stool culture for active C. difficile * Pregnant women * Patients under antibiotic and/or probiotic treatment within 10 days prior to Visit 1.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ulcerative colitis (disorder) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Edoardo Savarino
RECRUITINGPadova, 352121, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ancient wisdom meets AI: could TCM features sharpen colorectal screening?
- Can a mediterranean diet and Time-Restricted eating tame gut inflammation?
- Can a biologic drug calm the gut in ulcerative colitis? a Real-World trial seeks answers
- AI may predict ulcerative colitis severity before a scope — a study puts it to the test
- New oral drug for inflammatory bowel disease enters first human tests
- Can a medical food fight malnutrition in IBD?